Prognostic Significance of β-Catenin Expression in Osteosarcoma: A Meta-Analysis

Overview

Journal Front Oncol

Specialty Oncology

Date 2020 Apr 25

PMID 32328456

Citations 7

Authors

Xiaoliang Xie

Yumei Li

Haixia Zhu

Zhixing Kuang

Deta Chen

Tianyou Fan

Affiliations

Soon will be listed here.

Abstract

β-catenin plays a crucial role in the progression of osteosarcoma. However, the clinical significance of β-catenin over-expression in osteosarcoma still remains unclear. Thus, we performed a meta-analysis of studies that evaluated the impact of β-catenin on metastasis and overall survival (OS) in osteosarcoma. We searched PubMed, The Cochrane Library, Embase, Springer, Science Direct, OVID, Weipu, Wanfang and China National Knowledge Internet (CNKI) databases from their start year up to Aug.2019. Individual hazard ratios (HRs) and 95% confidence intervals (CIs) were extracted and pooled HRs with 95% CIs or odd ratio (OR) were used to evaluate the relationships between β-catenin over-expression and metastasis and overall survival in osteosarcoma. Eight related studies involving 521 patients were qualified for this meta-analysis. Results showed that over-expression of β-catenin was significantly correlated with metastasis (OR = 3.31, 95% CI = 2.08-5.24, < 0.001) and overall survival (HR = 2.32, 95% CI = 1.48-363, = 0.02). The meta-analysis revealed that over-expression of β-catenin might be associated with distant metastasis and overall survival in osteosarcoma, which reminds that β-catenin acts as a prognostic biomarker and it can guide the clinical therapy in osteosarcoma patients.

Citing Articles

Inhibition of mitochondrial OMA1 ameliorates osteosarcoma tumorigenesis.

Chen L, Chen D, Pan Y, Mo Y, Lai B, Chen H Cell Death Dis. 2024; 15(11):786.

PMID: 39487118 PMC: 11530700. DOI: 10.1038/s41419-024-07127-1.

: NF-κB Inhibition as an Alternative to Overcome Osteosarcoma Heterogeneity.

Medeiros M, Guenka S, Bastos D, Oliveira K, Brassesco M Pharmaceuticals (Basel). 2024; 17(6).

PMID: 38931401 PMC: 11206879. DOI: 10.3390/ph17060734.

Signal Pathways and microRNAs in Osteosarcoma Growth and the Dual Role of Mesenchymal Stem Cells in Oncogenesis.

Todosenko N, Khlusov I, Yurova K, Khaziakhmatova O, Litvinova L Int J Mol Sci. 2023; 24(10).

PMID: 37240338 PMC: 10219319. DOI: 10.3390/ijms24108993.

The immune landscape of solid pediatric tumors.

Sherif S, Roelands J, Mifsud W, Ahmed E, Raynaud C, Rinchai D J Exp Clin Cancer Res. 2022; 41(1):199.

PMID: 35690832 PMC: 9188257. DOI: 10.1186/s13046-022-02397-z.

A Data Science Approach for the Identification of Molecular Signatures of Aggressive Cancers.

Barbosa-Silva A, Magalhaes M, Silva G, Silva F, Goncalves Carneiro F, Carels N Cancers (Basel). 2022; 14(9).

PMID: 35565454 PMC: 9103663. DOI: 10.3390/cancers14092325.

References

Isakoff M, Bielack S, Meltzer P, Gorlick R . Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. J Clin Oncol. 2015; 33(27):3029-35. PMC: 4979196. DOI: 10.1200/JCO.2014.59.4895. View

Ma Y, Zhu B, Liu X, Yu H, Yong L, Liu X . Inhibition of oleandrin on the proliferation show and invasion of osteosarcoma cells in vitro by suppressing Wnt/β-catenin signaling pathway. J Exp Clin Cancer Res. 2015; 34:115. PMC: 4596494. DOI: 10.1186/s13046-015-0232-8. View

Deng Z, Niu G, Cai L, Wei R, Zhao X . The prognostic significance of CD44V6, CDH11, and β-catenin expression in patients with osteosarcoma. Biomed Res Int. 2013; 2013:496193. PMC: 3732612. DOI: 10.1155/2013/496193. View

Faisham W, Mat Saad A, Alsaigh L, Nor Azman M, Kamarul Imran M, Biswal B . Prognostic factors and survival rate of osteosarcoma: A single-institution study. Asia Pac J Clin Oncol. 2015; 13(2):e104-e110. DOI: 10.1111/ajco.12346. View

Anderson M . Update on Survival in Osteosarcoma. Orthop Clin North Am. 2015; 47(1):283-92. DOI: 10.1016/j.ocl.2015.08.022. View

Kager L, Tamamyan G, Bielack S . Novel insights and therapeutic interventions for pediatric osteosarcoma. Future Oncol. 2016; 13(4):357-368. DOI: 10.2217/fon-2016-0261. View

Tian J, He H, Lei G . Wnt/β-catenin pathway in bone cancers. Tumour Biol. 2014; 35(10):9439-45. DOI: 10.1007/s13277-014-2433-8. View

Yang Z, Li X, Yang Y, He Z, Qu X, Zhang Y . Long noncoding RNAs in the progression, metastasis, and prognosis of osteosarcoma. Cell Death Dis. 2016; 7(9):e2389. PMC: 5059871. DOI: 10.1038/cddis.2016.272. View

Lu Y, Guan G, Chen J, Hu B, Sun C, Ma Q . Aberrant CXCR4 and β-catenin expression in osteosarcoma correlates with patient survival. Oncol Lett. 2015; 10(4):2123-2129. PMC: 4579913. DOI: 10.3892/ol.2015.3535. View

10.

Ren Z, Liang S, Yang J, Han X, Shan L, Wang B . Coexpression of CXCR4 and MMP9 predicts lung metastasis and poor prognosis in resected osteosarcoma. Tumour Biol. 2015; 37(4):5089-96. DOI: 10.1007/s13277-015-4352-8. View

11.

Shang S, Hua F, Hu Z . The regulation of β-catenin activity and function in cancer: therapeutic opportunities. Oncotarget. 2017; 8(20):33972-33989. PMC: 5464927. DOI: 10.18632/oncotarget.15687. View

12.

Bishop M, Janeway K, Gorlick R . Future directions in the treatment of osteosarcoma. Curr Opin Pediatr. 2015; 28(1):26-33. PMC: 4761449. DOI: 10.1097/MOP.0000000000000298. View

13.

Mei X, Su H, Song J, Dong L . Prognostic significance of β-catenin expression in patients with non-small cell lung cancer: a meta-analysis. Biosci Trends. 2013; 7(1):42-9. View

14.

Li R, Liu J, Wu H, Liu L, Wang L, Zhang S . TIKI2 suppresses growth of osteosarcoma by targeting Wnt/β-catenin pathway. Mol Cell Biochem. 2014; 392(1-2):109-16. DOI: 10.1007/s11010-014-2023-5. View

15.

Zhang D, Li X, Lang J . Prognostic Value of β-catenin Expression in Breast Cancer Patients: a Meta-analysis. Asian Pac J Cancer Prev. 2015; 16(14):5625-33. DOI: 10.7314/apjcp.2015.16.14.5625. View

16.

Bao Z, Zhang C, Xiao Y, Zhou J, Tao Y, Chai D . Over-expression of Sox4 and β-catenin is associated with a less favorable prognosis of osteosarcoma. J Huazhong Univ Sci Technolog Med Sci. 2016; 36(2):193-199. DOI: 10.1007/s11596-016-1565-z. View

17.

Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. PMC: 1920534. DOI: 10.1186/1745-6215-8-16. View

18.

Lindsey B, Markel J, Kleinerman E . Osteosarcoma Overview. Rheumatol Ther. 2016; 4(1):25-43. PMC: 5443719. DOI: 10.1007/s40744-016-0050-2. View

19.

Harrison D, Geller D, Gill J, Lewis V, Gorlick R . Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer Ther. 2017; 18(1):39-50. DOI: 10.1080/14737140.2018.1413939. View

20.

Meyers P, Gorlick R . Osteosarcoma. Pediatr Clin North Am. 1997; 44(4):973-89. DOI: 10.1016/s0031-3955(05)70540-x. View